Results 101 to 110 of about 24,935 (185)

Emergence and spread of NA-I223V and NA-S247N double-mutant A(H1N1)pdm09 influenza viruses with reduced oseltamivir susceptibility in the Netherlands and beyond, 2023 to 2026. [PDF]

Euro Surveill
Felix Garza Z, Eggink D, Bagheri M, van den Brink S, Goderski G, Pronk M, Lexmond P, Hooiveld M, van Gageldonk-Lafeber R, Koel B, Fouchier R, Meijer A.   +11 more
europepmc   +1 more source

Impact of Oseltamivir and Diabetes Development

Background/Objectives: Influenza is a major global health challenge, causing thousands of deaths annually. Antiviral drugs, particularly oseltamivir, a neuraminidase inhibitor, have become essential therapeutic options due to their oral bioavailability ...
Pei-Hua Chuang, Pei-Hsun Wu, Tsai-Ching Hsu, Yu-Chun Pan, Chih-Chen Tzang, Bor-Show Tzang, I-Ying Kuo   +6 more
core   +1 more source

The association of empirical treatment with oseltamivir with the outcome of critically ill patients admitted with severe acute respiratory illness (SARI). [PDF]

SAGE Open Med
Khan RM, AlMarashi LM, Temsah MH, Al Ghamdi GAA, Sadat M, Bin Humaid F, Jose J, Al-Hameed F, Al Khatib K, AlObaidi M, Alanezi MS, Al-Basseet FF, Alanazi R, Arabi Y.   +13 more
europepmc   +1 more source

Oseltamivir for Treatment of Influenza Among Outpatient Veterans: Target Trial Emulation. [PDF]

Open Forum Infect Dis
Yan L, Li Y, Vergun R, Rajeevan N, Berry K, Mutalik P, Anderson K, Vales J, Hynes DM, Bui DP, Lin HM, Huang Y, Aslan M, Ioannou GN, Bajema KL.   +14 more
europepmc   +1 more source

A randomised, open-label clinical study on the efficacy of baloxavir marboxil and oseltamivir for post-exposure prevention of influenza in a hospital setting: a study protocol. [PDF]

BMJ Open
Li X, Chu Z, Peng M, Yan K, Guan Y, Yang C, Xu J, Qiu L, Liu T.   +8 more
europepmc   +1 more source

Study protocol for a phase II clinical trial evaluating the safety and efficacy of favipiravir injection combined with oseltamivir in influenza treatment. [PDF]

BMJ Open
Hikida S, Nomoto H, Uemura Y, Suzuki T, Izumikawa K, Ohge H, Yamato M, Kato Y, Hase R, Aoyagi T, Hagiya H, Nukui Y, Yamamoto K, Takesue Y, Sawada K, Shimizu Y, Miyamoto S, Tamura N, Takahashi K, Saito S, Miyazaki K, Morino E, Tokita D, Ohmagari N.   +23 more
europepmc   +1 more source

Oseltamivir Resistance in Human Influenza A(H5N1) and A(H7N9) Infections: A Mini Review. [PDF]

Open Forum Infect Dis
Abed Y, Boivin G.
europepmc   +1 more source

Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit. [PDF]

Emerg Microbes Infect
Nie L, Chen Y, Wang P, Xie Y, Zuo Y, Zhang Y, Gu B, Lin K, Li J, Zhang L.   +9 more
europepmc   +1 more source

Intensive Chemoprophylaxis for Nursing Home Influenza Outbreaks-Reply. [PDF]

JAMA Intern Med
Zullo AR, Silva JBB, Gravenstein S.
europepmc   +1 more source

Transient Platelet Elevation Following Oseltamivir Administration in Pediatric Chronic Immune Thrombocytopenia. [PDF]

Cureus
Yamamoto S, Furui Y, Okura E, Sakamoto K, Hirabayashi K, Saito S, Nakazawa Y.   +6 more
europepmc   +1 more source